Getein Biotech, Inc (SHSE: 603387)
Health Care · Biotechnology · CN
CN¥9.42
+0.32% today · +6.4% 1Y
Getein Biotech, Inc (SHSE: 603387) operates in the Biotechnology industry within the Health Care sector. The company is valued at $710.67M and employs 1,733 people.
Over the last twelve months the share price has gained 6.4%, trading between 7.37 and 11.42.
Tweenvest scores Getein Biotech, Inc across four factors: quality 73/100, value 42/100, growth 11/100, dividend 65/100. Its strongest factor is quality.
603387 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $710.67M
- Revenue (TTM)
- $155.87M
- P/E
- 20.45
- EPS
- 0.46
- Dividend yield
- 3.18%
- Beta (5Y)
- -0.05
- 52-week high
- CN¥11.42
- 52-week low
- CN¥7.37
- Avg volume (3M)
- —
- Shares outstanding
- 507.15M
- Employees
- 1,733
- Next earnings
- —
About Getein Biotech, Inc
Getein Biotech, Inc. is an enterprise primarily focused on the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) solutions. Founded in 2002 and based in Nanjing, China, the company offers a comprehensive array of diagnostic products. This includes a variety of diagnostic reagents, advanced analytical instruments, and crucial calibrators. Getein also supplies foundational raw materials for reagents, such as monoclonal and polyclonal antibodies, antigens, antiserum, and microspheres. Its extensive product line caters to diverse medical fields, encompassing diagnostics for cardiac markers, inflammatory conditions, renal function, blood coagulation, thyroid disorders, fertility assessments, diabetes care, and thrombus detection. These offerings broadly serve applications in cardiovascular, inflammatory, diabetes, reproductive, renal, hepatic, and other key health areas.
- ISIN
- CNE100002RR9
- Founded
- 2002
- Listed since
- Jul 17, 2017
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.61 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.27 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.80 | +0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.52 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.35 | -7.86% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.